|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Helical tomotherapy and volumetric modulated arc therapy:New therapeutic arms in the breast cancer radiotherapy显示文摘AIM To analyse clinical and dosimetric results of helical tomotherapy(HT) and volumetric modulated arc therapy(VMAT) in complex adjuvant breast and nodes irradiation.METHODS Seventy-three patients were included(31 HT and 42 VMAT). Dose were 63.8 Gy(HT) and 63.2 Gy(VMAT) in the tumour bed, 52.2 Gy in the breast, 50.4 Gy in supraclavicular nodes(SCN) and internal mammary chain(IMC) with HT and 52.2 Gy and 49.3 Gy in IMC and SCN with VMAT in 29 fractions. Margins to particle tracking velocimetry were greater in the VMAT cohort(7 mm vs 5 mm).RESULTS For the HT cohort, the coverage of clinical target volumes was as follows: Tumour bed: 99.4% ± 2.4%; breast: 98.4% ± 4.3%; SCN: 99.5% ± 1.2%; IMC:96.5% ± 13.9%. For the VMAT cohort, the coverage was as follows: Tumour bed: 99.7% ± 0.5%, breast: 99.3% ± 0.7%; SCN: 99.6% ± 1.4%; IMC: 99.3% ± 3%. For ipsilateral lung, Dmean and V20 were 13.6 ± 1.2 Gy, 21.1% ± 5%(HT) and 13.6 ± 1.4 Gy, 20.1% ± 3.2%(VMAT). Dmean and V30 of the heart were 7.4 ± 1.4 Gy, 1% ± 1%(HT) and 10.3 ± 4.2 Gy, 2.5% ± 3.9%(VMAT). For controlateral breast Dmean was 3.6 ± 0.2 Gy(HT) and 4.6 ± 0.9 Gy(VMAT). Acute skin toxicity grade 3 was 5% in the two cohorts.CONCLUSION HT and VMAT in complex adjuvant breast irradiation allow a good coverage of target volumes with an acceptable acute tolerance. A longer follow-up is needed to assess the impact of low doses to healthy tissues. | Olivier Lauche Youlia M Kirova Pascal Fenoglietto Emilie Costa Claire Lemanski Celine Bourgier Olivier Riou David Tiberi Francois Campana Alain Fourquet David Azria | 2016 | World Journal of Radiology2016，8，8： | 7 |
| 2 | External beam radiation therapy and interstitial brachytherapy in the treatment of anal canal carcinomas: a series of 70 patients显示文摘 | Dubois JB Azria D Ychou M | 2003 | Bull Cancer2003，90，12： | 1 |
| 3 | Comparison of two neoadjuvant chemoradiotherapyregimens for locally advanced rectal cancer: results of thephase III trial ACCORD 12/0405-Prodige 2显示文摘 | GERARD JP AZRIA D GOURGOU-BOURGADE S etal | 2010 | J Clin On-col2010，28，10： | 1 |
| 4 | The analgesic role of calcitonin following osteoporotic fracture 显示文摘 | Silveran SL Azria M | 2002 | Osteoporos Int2002，13，1： | 1 |
| 5 | High-Dose Split-Course Radiation Therapy for Anal Cancer: Outcome Analysis Regarding the Boost Strategy (CORS-03 Study)显示文摘 | Jean-Michel Hannoun-Levi Cécile Ortholan Michel Resbeut Eric Teissier Philippe Ronchin Didier Cowen Audrey Zaccariotto Karen Bénézery Eric Fran?ois Naji Salem Steve Ellis David Azria Jean-Pierre Gerard | 2011 | International Journal of Radiation Oncology Biology Physics2011，，3： | 1 |
| 6 | Concurrent or sequential acljuvant letrozole and rauio therapy cofter conservative surgery for ecrly 2 stagel breast cancer(CO2HO2RT):a phase 2 ranclonised trizal显示文摘 | Azria D Belkacemi Y Romieu G | 2010 | Lancet Oncal2010，11，3： | 1 |
| 7 | Enhancement of radiation therapy by tumor necrosis factor alpha in human colon cancer using a bispecific antibody显示文摘 | Azria D Dorvillius M Gourgou S | 2003 | Int J Radiat Oncol Biol Phys2003，1，5： | 1 |
| 8 | Letrozole sensitizes breast cancer cells to ionizing radiation显示文摘 | Azria D Larbouret C Cunat S | 2005 | Breast Cancer Res2005，7，1： | 1 |
| 9 | Gemcitabine and ionizing radia-tions;radiosensitization or radio-chemotherapy combination显示文摘 | Azria D Jacot W Prost P | 2002 | Bull Cancer2002，89，4： | 1 |
| 10 | Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network显示文摘 | Omlin A Amichetti M Azria D | 2006 | Lancet Oncol2006，7，8： | 1 |
| 11 | Vaginal mesh erosion 7 years after a sacral colpopexy 显示文摘 | Deval B RafII A Azria E | 2003 | Acta Obstet Gynecol Scand2003，82，： | 1 |
| 12 | The epidermalgrowth factor receptor(EGFR)in head and neck cancer:its roleand treatment implications显示文摘 | Zimmernmnn M Zouhair A Azria D | 2006 | Radiat Oncol2006，1，1： | 1 |
| 13 | Salmoncalcitonin: a review of current and future therapeu-tic indications显示文摘 | Chesnut CH Azria M Silverman S | 2008 | April2008，19，4： | 1 |
| 14 | Salman calcitonin:a review of current and future therapeutic indications显示文摘 | chesnut CH 3rd Azria M silverman S | 2008 | Osteoporos Int2008，19，4： | 1 |
| 15 | Salmon calcitonin: a review ofcurrent and future the rapeutic indications显示文摘 | Chesnut CH 3rd Azria M Silverman S | 2008 | Osteoros Int2008，19，4： | 1 |
| 16 | Compari- son of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase IIItrial ACCORD 12/0405-Prodige 2显示文摘 | Gerard JP Azria D Gourgou-Bourgade S | 2010 | J Clin Oncol2010，28，： | 1 |
| 17 | Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer:results of the phaseⅢtrial ACCORD 12/0405-Prodige 2显示文摘 | Grrard J P Azria D Gourgou-Bourgade S | 2010 | J Clin Oncol2010，28，10： | 1 |
| 18 | Neurocognitive func- tion impairment after whole brain radiotherapy for brain me- tastases: actual assessment显示文摘 | Tallet AV Azria D Barlesi F | 2012 | Radiat Oncol2012，7，1： | 1 |
| 19 | Gemcitabine and pancreatic cancer显示文摘 | Prost P Ychou M Azria D | 2002 | Bull Cancer2002，，89： | 1 |
| 20 | The analgesic role of calcitonin following osteoporotic fracture显示文摘 | Silverman S L Azria M | 2002 | Osteoporos Int2002，13，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员